BLA 761058 · Boehringer Ingelheim
Cyltezo
Adalimumab-Adbm · Injection
Last checked: Nov 20, 2026Latest source record: Oct 16, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2017
Aug 25, 2017
Approved uses
7
Original approval plus efficacy supplements
Registered trials
523
198 Phase 3, 51 recruiting
FAERS reports
268
58 serious, 3 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: SERIOUS INFECTIONS AND MALIGNANCY WARNING: SERIOUS INFECTIONS AND MALIGNANCY See full prescribing information for complete boxed warning . SERIOUS INFECTIONS ( 5.1 , 6.1 ): Increased risk of serious infections leading to hospitalization or death, including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis), and infections due to other opportunistic pathogens. Discontinue CYLTEZO if a patient develops a serious infection or sepsis during treatment. Perform test for latent TB; if positive, start treatment for TB prior to starting CYLTEZO. Monitor all patients for active TB during treatment, even if initial latent TB test is negative. MALIGNANCY ( 5.2 ): Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers including adalimumab products. Post-marketing cases of...
What it is approved for
From the label in effect May 22, 2026.
CYLTEZO is a tumor necrosis factor (TNF) blocker indicated for: Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis . ( 1.1 ) Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. ( 1.2 ) Reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis . (1.3) Reducing signs and symptoms in adult patients with active ankylosing spondylitis . ( 1.4 ) Treatment of moderately to severely active Crohn's disease in adults and pediatric patients 6 years of age and older. ( 1.5 ) Treatment of moderately to severely active ulcerative colitis in adult patients. ( 1.6 ) Limitations of Use: Effectiveness has not been established in patients who have lost response to or were intolerant to TNF blockers. Treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. ( 1.7 ) Treatment of moderate to severe hidradenitis suppurativa in patients 12 years of age and older. ( 1.8 ) Treatment of non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older. ( 1.9 ) 1.1 Rheumatoid Arthritis CYLTEZO is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. CYLTEZO can be used alone or in...
Mechanism: Adalimumab products bind specifically to TNF-alpha and block its interaction with the p55 and p75 cell surface TNF receptors. Adalimumab products also lyse surface TNF expressing cells in vitro in the presence of complement. Adalimumab products do not bind or inactivate lymphotoxin (TNF-beta). TNF is a naturally occurring cytokine that is involved in normal inflammatory and immune responses. Elevated concentrations of TNF are found in the synovial fluid of patients with RA, JIA, PsA, and AS and play an important role in both the pathologic inflammation and the joint destruction that are...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 20, 2025 Supplement 31 · Efficacy LetterLabel
- Apr 30, 2024 Supplement 26 · Efficacy LabelLetter
- Jun 30, 2023 Supplement 18 · Efficacy Label
- May 18, 2023 Supplement 16 · Efficacy LetterLabel
- Mar 22, 2023 Supplement 13 · Efficacy LetterLabel
- Oct 15, 2021 Supplement 8 · Efficacy LabelLetter
- Aug 25, 2017 Original approval · Type 2 - New Active Ingredient LabelLetterReview
1 products under this application
- CYLTEZO · ADALIMUMAB-ADBM 40MG/0.8ML · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Adalimumab" as an intervention, any sponsor and status, largest first.
- A Study to Assess the Safety and Efficacy of Adalimumab When Added to Inadequate Standard Anti-Rheumatic Therapy in Patients With Active Rheumatoid ArthritisPivotal-lookingCompleted
AbbottIndustry
NCT00448383 · 6,610 participants · Start Sep 2002 · Primary completion Nov 2004
Drug: adalimumab · For: Rheumatoid Arthritis
- Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid ArthritisPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT02092467 · 4,372 participants · Start Mar 14, 2014 · Primary completion Jul 22, 2020
Drug: tofacitinib; tofacitinib and 2 more · For: Arthritis, Rheumatoid
Sites: Birmingham, Alabama; Huntsville, Alabama; Tuscaloosa, Alabama · 345 sites in all
- Study of Human Anti-TNF Monoclonal Antibody D2E7 in Subjects With Active Rheumatoid ArthritisPivotal-lookingCompleted
AbbottIndustry
NCT00049751 · 3,000 participants · Start Sep 2002
Drug: Adalimumab · For: Rheumatoid Arthritis
Sites: Mobile, Alabama; Apple Valley, California; Bakersfield, California · 54 sites in all
- A Study of Baricitinib (LY3009104) in Participants With Rheumatoid ArthritisPivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT03915964 · 2,659 participants · Start Apr 25, 2019 · Primary completion May 28, 2025
Drug: Baricitinib; TNF Inhibitor · For: Rheumatoid Arthritis
Sites: Flagstaff, Arizona; Gilbert, Arizona; Glendale, Arizona · 261 sites in all
- Efficacy of HUMIRA in Subjects With Active Rheumatoid ArthritisPivotal-lookingCompleted
AbbottIndustry
NCT00234897 · 1,938 participants · Start Aug 2004
Drug: adalimumab · For: Rheumatoid Arthritis
Sites: North Chicago, Illinois
- Filgotinib in Combination With Methotrexate in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to MethotrexatePivotal-lookingCompleted
Gilead SciencesGilead Sciences (GILD)
NCT02889796 · 1,759 participants · Start Aug 30, 2016 · Primary completion Jul 4, 2018
Drug: Filgotinib; Placebo to match filgotinib and 3 more · For: Rheumatoid Arthritis
Sites: Huntsville, Alabama; Phoenix, Arizona; Tucson, Arizona · 230 sites in all
AbbVieAbbVie (ABBV)
NCT03104400 · 1,705 participants · Start Apr 27, 2017 · Primary completion Sep 26, 2019
Drug: Adalimumab; Upadacitinib and 2 more · For: Psoriatic Arthritis
Sites: Huntsville, Alabama; Peoria, Arizona; Phoenix, Arizona · 345 sites in all
- Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo and Adalimumab, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active DiseasePivotal-lookingCompleted
R-Pharm International, LLCIndustry
NCT02760407 · 1,648 participants · Start Jun 6, 2016 · Primary completion Aug 2, 2019
Drug: Olokizumab 64mg q4w; Olokizumab 64mg q2w and 2 more · For: Rheumatoid Arthritis
Sites: Mesa, Arizona; Phoenix, Arizona; Sun City, Arizona · 203 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- device malfunction26
- drug ineffective18
- injection site haemorrhage18
- pain18
- injection site pain17
- off label use16
- device issue14
- diarrhoea12
- arthralgia11
- wrong technique in product usage process11
- needle issue10
- fatigue9
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2018 | 1 |
| 2023 | 4 |
| 2024 | 25 |
| 2025 | 95 |
| 2026 | 143 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa.
Kimball AB, Okun MM, Williams DA, et al. · N Engl J Med 2016 · Clinical Trial, Phase III, Multicenter Study
- Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis.
Sands BE, Peyrin-Biroulet L, Loftus EV, et al. · N Engl J Med 2019 · Clinical Trial, Phase III, Comparative Study
- Comparative efficacy of biologics and oral agents in palmoplantar psoriasis and palmoplantar pustulosis: A systematic review and network meta-analysis of randomized clinical trials.
Spencer RK, Jin JQ, Elhage KG, et al. · J Am Acad Dermatol 2023 · Letter, Network Meta-Analysis
- Adalimumab in Patients with Active Noninfectious Uveitis.
Jaffe GJ, Dick AD, Brézin AP, et al. · N Engl J Med 2016 · Clinical Trial, Phase III, Multicenter Study
- Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis.
Taylor PC, Keystone EC, van der Heijde D, et al. · N Engl J Med 2017 · Clinical Trial, Phase III, Comparative Study
- Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double-Blind, Randomized Controlled Trial.
Fleischmann R, Pangan AL, Song IH, et al. · Arthritis Rheumatol 2019 · Clinical Trial, Phase III, Randomized Controlled Trial
Sponsor: Boehringer Ingelheim
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.